Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170402 | 0.97 | P2RX7 (0.45) | P2RX7LMNATSHRNPC1RAB9A | |
| SCHEMBL4154113 | 0.74 | HPGD (0.43) | LMNAL3MBTL1RECQLHTTHDAC1 | |
| SCHEMBL4163322 | 0.71 | L3MBTL1 (0.41) | TSHRL3MBTL1NPC1RAB9AHTT | |
| SCHEMBL4173665 | 0.71 | HPGD (0.46) | LMNANPC1RAB9ARECQLHDAC1 | |
| SCHEMBL4159491 | 0.70 | GAA (0.49) | NPC1RAB9AGAA | |
| SCHEMBL4533236 | 0.70 | SIGMAR1 (0.46) | LMNATSHRL3MBTL1NPC1RAB9A | |
| SCHEMBL23579159 | 0.69 | NPC1 (0.56) | P2RX7TSHRNPC1RAB9AHTT | |
| SCHEMBL3184732 | 0.69 | HPGD (0.49) | LMNATSHRNPC1RAB9AHDAC1 | |
| SCHEMBL4159720 | 0.68 | NPC1 (0.41) | LMNATSHRL3MBTL1NPC1RAB9A | |
| SCHEMBL4160499 | 0.68 | P2RX7 (0.35) | P2RX7LMNATSHRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | LABORATORIOS SALVAT, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | PPARG, PPARD, TYRO3 | P2RX7 2513/4885LMNA 4048/4885TSHR 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.